


wherein the amount of the factor produced by the mutant is at least about two times more than the amount of the factor produced by the parent strain,
and wherein said factor has ^1H NMR shifts at about δ 1.5, 3.22, 3.29, 3.35, 3.43, 3.58, 3.73, 3.98, 4.07, 4.15, 4.25, and 4.35, and ^{13}C shifts at about 31.6, 37.2, 51.1, 53.3, 54.0, 54.4, 61.5, 61.6, 64.1, 65.6, 158.3, 170.7 and 171.3.

Please amend claim 19 as follows:

19. (once amended)



Please amend claim 20 as follows:

20. (once amended) The mutant of claim 18 wherein said *Bacillus thuringiensis* delta-endotoxin is selected from the group consisting of CryI, CryII, CryIII, CryIV, CryV and CryVI.

Please amend claim 21 as follows:

3/
21. (once amended) The mutant of claim 20 wherein said *Bacillus thuringiensis* delta-endotoxin is a CryIA delta-endotoxin.

Please cancel claim 22.

Please amend claim 23 as follows:

- B²
23. (once amended) A factor which is obtained by
- (a) culturing the mutant of said *Bacillus thuringiensis* subsp. *kurstaki* strain of claim 18 to produce said factor;
 - (b) recovering a supernatant of the culture of said mutant of step (a); and
 - (c) isolating said factor from said supernatant of step (b).
-

REMARKS

Claims 18-23 were rejected under 35 U.S.C. §112, second paragraph, as being indefinite on various grounds.

Applicants have canceled claim 22 and amended claims 18, 19, 20, 21 and 23 to delete reference to pesticidally active fragments, delete the second period in claim 19 and clarify claim 23 as being directed to the production of a factor.